Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC

• Status: Unknown status
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether in docetaxel pretreated advanced NSCLC patients with favorable clinical parameter(s) gefitinib can produce different outcomes from patients without favorable clinical parameter treated with irinotecan.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Camptothecin; Docetaxel; Gefitinib; Irinotecan

Criteria

Inclusion Criteria:

• aged 75 years or less

• histologically or cytologically confirmed non-small cell lung cancer

• advanced, metastatic or recurrent

• ECOG performance status 0 to 2

• one prior palliative chemotherapy including docetaxel

• measurable or evaluable indicator lesion(s)

• normal marrow, hepatic and renal function

• provision of written informed consent

Exclusion Criteria:

• active infection and/or severe comorbidities

• pregnant or breastfed women

• active CNS metastasis

• active bleeding in GI tract or elsewhere